🇺🇸 FDA
Patent

US 12227581

Anti-BCMA single domain antibodies and application thereof

granted A61KA61K40/11A61K40/31

Quick answer

US patent 12227581 (Anti-BCMA single domain antibodies and application thereof) held by SHENZHEN PREGENE BIOPHARMA CO., LTD. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SHENZHEN PREGENE BIOPHARMA CO., LTD.
Grant date
Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K40/11, A61K40/31, A61K40/4215, A61K48/005